Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Gains from Investment Securities (2016 - 2025)

International Stem Cell (ISCO) has disclosed Gains from Investment Securities for 16 consecutive years, with $12.5 million as the latest value for Q1 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $12.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $12.5 million, a N/A change, with the full-year FY2024 number at $12.5 million, changed N/A from a year prior.
  • Gains from Investment Securities was $12.5 million for Q1 2025 at International Stem Cell, roughly flat from $12.5 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $12.5 million in Q4 2024 to a low of $287471.0 in Q2 2021.
  • A 5-year average of $6.4 million and a median of $6.9 million in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 2287.4% in 2022; the steepest drop was 27.64% in 2022.
  • International Stem Cell's Gains from Investment Securities stood at $5.4 million in 2021, then rose by 27.64% to $6.9 million in 2022, then tumbled by 88.34% to $800000.0 in 2023, then surged by 1465.37% to $12.5 million in 2024, then decreased by 0.01% to $12.5 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Gains from Investment Securities are $12.5 million (Q1 2025), $12.5 million (Q4 2024), and $800000.0 (Q3 2023).